Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug, as US ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Wednesday cut its full-year sales and profit outlook amid lacklustre ...

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

Treasury Secretary Scott Bessent and U.S. Trade Representative Jamieson Greer are traveling to Switzerland on Thursday to meet Beijing's lead economic representative, potentially paving the way for ...

Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.